Autologous immune enhancement therapy against an advanced epithelioid sarcoma: A case report

Ratnavelu,Kananathan; Subramani,Baskar; Pullai,Chithra  Ramanathan; Krishnan,Kohila; Sugadan,Sheela  Devi; Rao,Manjunath  Sadananda; Veerakumarasivam,Abhi; Deng,Xuewen; Hiroshi,Terunuma

doi:10.3892/ol.2013.1247

Autologous immune enhancement therapy against an advanced epithelioid sarcoma: A case report

Authors:
- Kananathan Ratnavelu
- Baskar Subramani
- Chithra Ramanathan Pullai
- Kohila Krishnan
- Sheela Devi Sugadan
- Manjunath Sadananda Rao
- Abhi Veerakumarasivam
- Xuewen Deng
- Terunuma Hiroshi
View Affiliations

Affiliations: Nilai Cancer Institute (NCI) Hospital, Nilai 71800, Malaysia, Acharya Nagarjuna University, Andhra Pradesh 522510, India, Nichi-Asia Life Science Sdn. Bhd., Petaling Jaya 47810, Malaysia, Medical Genetics Laboratory, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Selangor Darul Ehsan, Malaysia, Nichi-In Centre for Regenerative Medicine, Chennai 600026, India, UPM-MAKNA Cancer Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia, Serdang, 43400, Selangor Darul Ehsan, Malaysia, Perdana University Graduate School of Medicine, Perdana University, Serdang 43400, Selangor Darul Ehsan, Malaysia, Biotherapy Institute of Japan, Tokyo 135-0051, Japan
Published online on: March 12, 2013 https://doi.org/10.3892/ol.2013.1247
Pages: 1457-1460

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Rare types of cancer are often not effectively treated by approaches such as chemotherapy and radiotherapy, although their side-effects persist. Immunotherapy has been gaining attention worldwide with growing examples of its anticancer activity demonstrated in vivo. This case report describes a 35‑year‑old male who suffered from advanced epithelioid sarcoma and underwent 18 cycles of chemotherapy without any significant response, who suffered adverse effects that caused lung collapse. A notable response was observed following the administration of autologous immune enhancement therapy (AIET), which involves a process of isolation, activation and expansion of natural killer (NK) and T cells, which were obtained from the patient's own (autologous) peripheral blood. With the present data and the response of the patient to AIET, it may be proposed that AIET is beneficial for patients suffering from advanced epithelioid sarcoma without producing adverse effects.

View Figures

View References

1	Demetri GD, Baker LH, Benjamin RS, et al: Soft tissue sarcoma. J Natl Compr Canc Netw. 5:364–399. 2007.PubMed/NCBI
2	Pedrazzoli P, Secondino S, Perfetti V, Comoli P and Montagna D: Immunotherapeutic Intervention against Sarcomas. J Cancer. 2:350–356. 2011. View Article : Google Scholar : PubMed/NCBI
3	Ferrari A, Miceli R, Casanova M, et al: The symptom interval in children and adolescents with soft tissue sarcomas. Cancer. 116:177–183. 2010.PubMed/NCBI
4	Cormier JN and Pollock RE: Soft tissue sarcomas. CA Cancer J Clin. 54:94–109. 2004. View Article : Google Scholar
5	Brady MS, Gaynor JJ and Brennan MF: Radiation-associated sarcoma of bone and soft tissue. Arch Surg. 127:1379–1385. 1992. View Article : Google Scholar : PubMed/NCBI
6	Zahm SH and Fraumeni JF Jr: The epidemiology of soft tissue sarcoma. Semin Oncol. 24:504–514. 1997.PubMed/NCBI
7	Hardell L and Sandström A: Case-control study: soft-tissue sarcomas and exposure to phenoxyacetic acids or chlorophenols. Br J Cancer. 39:711–717. 1979. View Article : Google Scholar : PubMed/NCBI
8	Smith AH, Pearce NE, Fisher DO, Giles HJ, Teague CA and Howard JK: Soft tissue sarcoma and exposure to phenoxyherbicides and chlorophenols in New Zealand. J Natl Cancer Inst. 73:1111–1117. 1984.PubMed/NCBI
9	Mori K, Rédini F, Gouin F, Cherrier B and Heymann D: Osteosarcoma: current status of immunotherapy and future trends (Review). Oncol Rep. 15:693–700. 2006.PubMed/NCBI
10	Wolf PS, Flum DR, Tanas MR, Rubin BP and Mann GN: Epithelioid sarcoma: the University of Washington experience. Am J Surg. 196:407–412. 2008. View Article : Google Scholar
11	Gough NJ, Smith C, Ross JR, Riley J and Judson I: Symptom burden, survival and palliative care in advanced soft tissue sarcoma. Sarcoma. 2011:3251892011. View Article : Google Scholar : PubMed/NCBI
12	Coindre JM, Terrier P, Guillou L, et al: Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 91:1914–1926. 2001. View Article : Google Scholar
13	Sinha S and Peach AH: Diagnosis and management of soft tissue sarcoma. BMJ. 341:c71702010. View Article : Google Scholar : PubMed/NCBI
14	Grimer R, Judson I, Peake D and Seddon B: Guidelines for the management of soft tissue sarcomas. Sarcoma. 2010:5061822010.PubMed/NCBI
15	Clark MA, Fisher C, Judson I and Thomas JM: Soft-tissue sarcomas in adults. N Engl J Med. 353:701–711. 2005. View Article : Google Scholar : PubMed/NCBI
16	Buddingh EP, Schilham MW, Ruslan SE, et al: Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol Immunother. 60:575–586. 2011. View Article : Google Scholar : PubMed/NCBI
17	Cho D and Campana D: Expansion and activation of natural killer cells for cancer immunotherapy. Korean J Lab Med. 29:89–96. 2009. View Article : Google Scholar : PubMed/NCBI
18	Matar P, Alaniz L, Rozados V, et al: Immunotherapy for liver tumors: present status and future prospects. J Biomed Sci. 16:302009. View Article : Google Scholar : PubMed/NCBI
19	Manjunath SR, Ramanan G, Dedeepiya VD, et al: Autologous immune enhancement therapy in recurrent ovarian cancer with metastases: a case report. Case Rep Oncol. 5:114–118. 2012. View Article : Google Scholar : PubMed/NCBI
20	Maki RG: Soft tissue sarcoma as a model disease to examine cancer immunotherapy. Curr Opin Oncol. 13:270–274. 2001. View Article : Google Scholar : PubMed/NCBI
21	Maki RG: Future directions for immunotherapeutic intervention against sarcomas. Curr Opin Oncol. 18:363–368. 2006. View Article : Google Scholar : PubMed/NCBI
22	Takada M, Terunuma H, Deng X, et al: Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach. Breast Cancer. 18:64–67. 2011. View Article : Google Scholar : PubMed/NCBI
23	Montagna D, Turin I, Schiavo R, et al: Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor. Cytotherapy. 14:80–90. 2012. View Article : Google Scholar : PubMed/NCBI
24	Valle AA and Kraybill WG: Management of soft tissue sarcomas of the extremity in adults. J Surg Oncol. 63:271–279. 1996. View Article : Google Scholar : PubMed/NCBI
25	Francescutti V and Skitzki JJ: Sarcomas and the immune system: implications for therapeutic strategies. Surg Oncol Clin N Am. 21:341–355. 2012. View Article : Google Scholar : PubMed/NCBI